https://www.taxtmi.com/caselaws?id=797992 Bulk drugs and active pharmaceutical ingredients (APIs) classifiable under Chapters 28 or 29 qualify as "drugs" where intended for use as components of pharmaceutical formulations, including testing, clinical research, bioavailability or bioequivalence studies. Sl. No. 226 of Schedule I to Notification No. 9/2025-Integrated Tax (Rate) is a description-based entry covering drugs and medicines under Chapter 30 or any other chapter; its reference to formulations made from bulk drugs does not restrict relief to finished dosage forms. This specific entry prevails over general chemical entries. IGST at 5% applies to eligible APIs on import, subject to verification that the particular API is not covered by the nil-rate exclusion under Sl. No. 113 of Notification No. 10/2025-Integrated Tax (Rate). en-us Mon, 24 Aug 2026 00:00:00 +0530 Tue, 01 Sep 2026 08:26:26 +0530 TaxTMI RSS Generator https://www.taxtmi.com/caselaws?id=797992 Bulk drugs and active pharmaceutical ingredients (APIs) classifiable under Chapters 28 or 29 qualify as "drugs" where intended for use as components of pharmaceutical formulations, including testing, clinical research, bioavailability or bioequivalence studies. Sl. No. 226 of Schedule I to Notification No. 9/2025-Integrated Tax (Rate) is a description-based entry covering drugs and medicines under Chapter 30 or any other chapter; its reference to formulations made from bulk drugs does not restrict relief to finished dosage forms. This specific entry prevails over general chemical entries. IGST at 5% applies to eligible APIs on import, subject to verification that the particular API is not covered by the nil-rate exclusion under Sl. No. 113 of Notification No. 10/2025-Integrated Tax (Rate). Case-Laws Customs Mon, 24 Aug 2026 00:00:00 +0530 https://www.taxtmi.com/caselaws?id=797992